OptiBiotix Health Plc (OPTI) - Net Assets
Based on the latest financial reports, OptiBiotix Health Plc (OPTI) has net assets worth GBX8.42 Million GBX (≈ $1.02K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.15 Million ≈ $1.11K USD) and total liabilities (GBX732.00K ≈ $89.06 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read OptiBiotix Health Plc total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX8.42 Million |
| % of Total Assets | 92.0% |
| Annual Growth Rate | 15.18% |
| 5-Year Change | -29.14% |
| 10-Year Change | 120.03% |
| Growth Volatility | 976.48 |
OptiBiotix Health Plc - Net Assets Trend (2008–2024)
This chart illustrates how OptiBiotix Health Plc's net assets have evolved over time, based on quarterly financial data. Also explore OptiBiotix Health Plc total assets for the complete picture of this company's asset base.
Annual Net Assets for OptiBiotix Health Plc (2008–2024)
The table below shows the annual net assets of OptiBiotix Health Plc from 2008 to 2024. For live valuation and market cap data, see OptiBiotix Health Plc (OPTI) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX8.40 Million ≈ $1.02K |
-5.34% |
| 2023-12-31 | GBX8.87 Million ≈ $1.08K |
-18.64% |
| 2022-12-31 | GBX10.90 Million ≈ $1.33K |
-39.99% |
| 2021-12-31 | GBX18.17 Million ≈ $2.21K |
+53.34% |
| 2020-12-31 | GBX11.85 Million ≈ $1.44K |
+137.91% |
| 2019-12-31 | GBX4.98 Million ≈ $606.08 |
-29.47% |
| 2018-11-30 | GBX7.06 Million ≈ $859.29 |
+0.24% |
| 2017-11-30 | GBX7.05 Million ≈ $857.26 |
+40.83% |
| 2016-11-30 | GBX5.00 Million ≈ $608.74 |
+31.08% |
| 2015-11-30 | GBX3.82 Million ≈ $464.39 |
-17.90% |
| 2014-11-30 | GBX4.65 Million ≈ $565.66 |
+3911.91% |
| 2013-11-30 | GBX115.88K ≈ $14.10 |
-73.68% |
| 2012-07-31 | GBX440.35K ≈ $53.58 |
-43.03% |
| 2010-07-31 | GBX773.00K ≈ $94.05 |
-4.57% |
| 2009-07-31 | GBX810.00K ≈ $98.55 |
-1.82% |
| 2008-07-31 | GBX825.00K ≈ $100.38 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OptiBiotix Health Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX585.00K | 6.97% |
| Common Stock | GBX1.96 Million | 23.33% |
| Other Comprehensive Income | GBX1.75 Million | 20.80% |
| Other Components | GBX4.11 Million | 48.90% |
| Total Equity | GBX8.40 Million | 100.00% |
OptiBiotix Health Plc Competitors by Market Cap
The table below lists competitors of OptiBiotix Health Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Siam Cement Public Company Limited
F:TCM1
|
$64.50K |
|
Coral Products
LSE:CRU
|
$64.85K |
|
Nostrum Oil & Gas PLC
LSE:NOG
|
$65.23K |
|
Aeorema Communications Plc
LSE:AEO
|
$65.64K |
|
GSTechnologies Ltd
LSE:GST
|
$63.65K |
|
Color Star Technology Co. Ltd.
NASDAQ:ADD
|
$63.13K |
|
Biome Technologies Plc
LSE:BIOM
|
$62.73K |
|
Digitalbox PLC
LSE:DBOX
|
$62.41K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OptiBiotix Health Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,872,000 to 8,398,000, a change of -474,000 (-5.3%).
- Net loss of 1,805,000 reduced equity.
- New share issuances of 1,285,000 increased equity.
- Other comprehensive income decreased equity by 525,000.
- Other factors increased equity by 571,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-1.80 Million | -21.49% |
| Share Issuances | GBX1.28 Million | +15.3% |
| Other Comprehensive Income | GBX-525.00K | -6.25% |
| Other Changes | GBX571.00K | +6.8% |
| Total Change | GBX- | -5.34% |
Book Value vs Market Value Analysis
This analysis compares OptiBiotix Health Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 59.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 59.45x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-07-31 | GBX103.84 | GBX5.10 | x |
| 2009-07-31 | GBX101.95 | GBX5.10 | x |
| 2010-07-31 | GBX97.29 | GBX5.10 | x |
| 2012-07-31 | GBX2.41 | GBX5.10 | x |
| 2013-11-30 | GBX0.16 | GBX5.10 | x |
| 2014-11-30 | GBX0.17 | GBX5.10 | x |
| 2015-11-30 | GBX0.05 | GBX5.10 | x |
| 2016-11-30 | GBX0.06 | GBX5.10 | x |
| 2017-11-30 | GBX0.08 | GBX5.10 | x |
| 2018-11-30 | GBX0.09 | GBX5.10 | x |
| 2019-12-31 | GBX0.06 | GBX5.10 | x |
| 2020-12-31 | GBX0.12 | GBX5.10 | x |
| 2021-12-31 | GBX0.19 | GBX5.10 | x |
| 2022-12-31 | GBX0.12 | GBX5.10 | x |
| 2023-12-31 | GBX0.10 | GBX5.10 | x |
| 2024-12-31 | GBX0.09 | GBX5.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OptiBiotix Health Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -207.47%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.08x
- Recent ROE (-21.49%) is above the historical average (-134.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -3.88% | 0.00% | 0.00x | 1.06x | GBX-114.50K |
| 2009 | -1.98% | 0.00% | 0.00x | 1.01x | GBX-97.00K |
| 2010 | -4.66% | 0.00% | 0.00x | 1.01x | GBX-113.30K |
| 2012 | -375.38% | -1022.92% | 0.19x | 1.91x | GBX-1.70 Million |
| 2013 | -1700.85% | 0.00% | 0.00x | 3.14x | GBX-1.64 Million |
| 2014 | -17.44% | 0.00% | 0.00x | 1.11x | GBX-1.28 Million |
| 2015 | -33.56% | -4542.55% | 0.01x | 1.15x | GBX-1.66 Million |
| 2016 | -26.42% | -450.51% | 0.05x | 1.15x | GBX-1.79 Million |
| 2017 | 27.11% | 998.05% | 0.02x | 1.09x | GBX1.20 Million |
| 2018 | -27.31% | -373.14% | 0.06x | 1.14x | GBX-2.62 Million |
| 2019 | -47.88% | -317.90% | 0.11x | 1.37x | GBX-2.86 Million |
| 2020 | 49.11% | 380.96% | 0.11x | 1.16x | GBX4.62 Million |
| 2021 | 34.52% | 282.92% | 0.11x | 1.11x | GBX4.45 Million |
| 2022 | 23.72% | 566.08% | 0.04x | 1.06x | GBX1.50 Million |
| 2023 | -22.98% | -316.61% | 0.07x | 1.06x | GBX-2.93 Million |
| 2024 | -21.49% | -207.47% | 0.10x | 1.08x | GBX-2.64 Million |
Industry Comparison
This section compares OptiBiotix Health Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OptiBiotix Health Plc (OPTI) | GBX8.42 Million | -3.88% | 0.09x | $64.10K |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About OptiBiotix Health Plc
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential… Read more